Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Ofatumumab versus Teriflunomide in Multiple Sclerosis

by Häring, Dieter A , Bar-Or, Amit , Tomic, Davorka , Goodyear, Alexandra , Kerloeguen, Cecile , Merschhemke, Martin , Montalban, Xavier , Coyle, Patricia K , Kakarieka, Algirdas , Selmaj, Krzysztof , Hauser, Stephen L , Pingili, Ratnakar , Comi, Giancarlo , Kappos, Ludwig , de Seze, Jerome , Ramanathan, Krishnan , Cross, Anne H , Li, Bingbing , Correale, Jorge , Willi, Roman , Leppert, David , Wiendl, Heinz , Cohen, Jeffrey A

in Adult / Antibodies / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / B-Lymphocytes / Brain / Brain - pathology / CD20 antigen / Cell activation / Clinical trials / Crotonates / Crotonates - adverse effects / Crotonates - therapeutic use / Disease Progression / Double-Blind Method / Female / Gadolinium / Human health and pathology / Humans / Injections, Subcutaneous / Injections, Subcutaneous - adverse effects / Kaplan-Meier Estimate / Lesions / Leukemia / Life Sciences / Lymphocytes B / Lymphocytes T / Magnetic Resonance Imaging / Male / Monoclonal antibodies / Multiple sclerosis / Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis, Relapsing-Remitting - drug therapy / Multiple Sclerosis, Relapsing-Remitting - pathology / Neuroimaging / Patients / Statistical analysis / T-Lymphocytes / Toluidines / Toluidines - adverse effects / Toluidines - therapeutic use

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Ofatumumab versus Teriflunomide in Multiple Sclerosis

2020

Confirm

Do you wish to request the book?

Ofatumumab versus Teriflunomide in Multiple Sclerosis

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Häring, Dieter A,

Bar-Or, Amit,

Tomic, Davorka,

Goodyear, Alexandra,

Kerloeguen, Cecile,

Merschhemke, Martin,

Montalban, Xavier,

Coyle, Patricia K,

Kakarieka, Algirdas,

Selmaj, Krzysztof,

Hauser, Stephen L,

Pingili, Ratnakar,

Comi, Giancarlo,

Kappos, Ludwig,

de Seze, Jerome,

Ramanathan, Krishnan,

Cross, Anne H,

Li, Bingbing,

Correale, Jorge,

Willi, Roman,

Leppert, David,

Wiendl, Heinz,

Cohen, Jeffrey A

2020

Overview

In two identical trials involving a total of 1882 patients with multiple sclerosis, the human anti-CD20 monoclonal antibody ofatumumab was associated with a lower annualized relapse rate than the pyrimidine-synthesis inhibitor teriflunomide, as well as fewer lesions on MRI.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Antibodies

/ Antibodies, Monoclonal, Humanized

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use

/ B-Lymphocytes

/ Brain